Belzutifan is more efficacious than everolimus in the treatment of metastatic renal cell carcinoma

Dr Guillermo De Velasco - University Hospital 12 de Octubre, Madrid, Spain
Belzutifan is more efficacious than everolimus in the treatment of metastatic renal cell carcinoma ( Dr Guillermo De Velasco - University Hospital 12 de Octubre, Madrid, Spain )
28 Feb 2025

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC

Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center, Seattle, Washington
Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC ( Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center, Seattle, Washington )
26 Feb 2025

ctDNA evaluation may play a prognostic role in stage III colon cancer treated with celecoxib

Dr Jonathan Andrew Nowak - Dana-Farber Cancer Institute, Boston, USA
ctDNA evaluation may play a prognostic role in stage III colon cancer treated with celecoxib ( Dr Jonathan Andrew Nowak - Dana-Farber Cancer Institute, Boston, USA )
26 Feb 2025

Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC

Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA
Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC ( Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA )
25 Feb 2025

Combining chemotherapy with cemiplimab for advanced penile cancer may serve as a viable first-line treatment option

Prof Amit Bahl - University Hospitals Bristol, Bristol, UK
Combining chemotherapy with cemiplimab for advanced penile cancer may serve as a viable first-line treatment option ( Prof Amit Bahl - University Hospitals Bristol, Bristol, UK )
24 Feb 2025

KIM-1 is a good prognostic and predictive biomarker in advanced renal cell carcinoma

Dr Wenxin Xu - Dana-Farber Cancer Institute, Boston, USA
KIM-1 is a good prognostic and predictive biomarker in advanced renal cell carcinoma ( Dr Wenxin Xu - Dana-Farber Cancer Institute, Boston, USA )
24 Feb 2025

Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer

Dr Anna Dorothea Wagner - Lausanne University Hospital, Lausanne, Switzerland
Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer ( Dr Anna Dorothea Wagner - Lausanne University Hospital, Lausanne, Switzerland )
21 Feb 2025

UGN-102 shows better results after 12 months of treatment for low-grade intermediate-risk NMIBC

Dr Sandip Prasad - Garden State Urology, Morristown, USA
UGN-102 shows better results after 12 months of treatment for low-grade intermediate-risk NMIBC ( Dr Sandip Prasad - Garden State Urology, Morristown, USA )
20 Feb 2025

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC

Prof Camillo Porta - University of Bari, Bari, Italy,
CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC ( Prof Camillo Porta -  University of Bari, Bari, Italy, )
20 Feb 2025

HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide, abiraterone acetate plus prednisolone

Dr Nima Sharifi - University of Miami Miller School of Medicine, Miami, USA
HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide, abiraterone acetate plus prednisolone ( Dr Nima Sharifi -  University of Miami Miller School of Medicine, Miami, USA )
20 Feb 2025

Enfortumab vedotin in combination with pembrolizumab shows improved survival rates in la/mUC

Prof Thomas Powles - Barts Cancer Institute, London, England
Enfortumab vedotin in combination with pembrolizumab shows improved survival rates in la/mUC ( Prof Thomas Powles - Barts Cancer Institute, London, England )
19 Feb 2025

SIOG 2024: Updates in radiation oncology

Dr Lucinda Morris - Crown Princess Mary Cancer Centre, Westmead, Australia
SIOG 2024: Updates in radiation oncology ( Dr Lucinda Morris - Crown Princess Mary Cancer Centre, Westmead, Australia )
19 Feb 2025